Across TCGA pan-cancer cohorts, MT-ND5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MT-ND5 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MT-ND5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MT-ND5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where MT-ND5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.870	0.545	.009	16	view →
LUAD	DFS	Median	All	0.644	0.953	.009	4	view →
PDAC	DFS	Quartile	II,III,IV	0.371	0.693	.012	3	view →
LSCC	OS	Median	II,III,IV	1.000	0.881	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MT-ND5 tumor-vs-normal RNA expression · all MT-ND5 data types